{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:17:10Z","timestamp":1787066230948,"version":"build-2736575974"},"reference-count":50,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We conducted a systematic review and a meta-analysis to assess the association of anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients. Articles were retrieved until January 8, 2021, by searching in seven electronic databases. The main outcome was all-cause mortality occurred during hospitalization. Data were combined using the general variance-based method on the effect estimate for each study. Separate meta-analyses according to type of COVID-19 patients (hospitalized or intensive care unit [ICU] patients), anticoagulants (mainly heparin), and regimens (therapeutic or prophylactic) were conducted. A total of 29 articles were selected, but 23 retrospective studies were eligible for quantitative meta-analyses. No clinical trial was retrieved. The majority of studies were of good quality; however, 34% did not distinguish heparin from other anticoagulants. Meta-analysis on 25,719 hospitalized COVID-19 patients showed that anticoagulant use was associated with 50% reduced in-hospital mortality risk (pooled risk ratio [RR]: 0.50, 95% confidence interval [CI]: 0.40\u20130.62; I\n          2: 87%). Both anticoagulant regimens (therapeutic and prophylactic) reduced in-hospital all-cause mortality, compared with no anticoagulation. Particularly in ICU patients, the anticoagulant therapeutic regimen was associated with a reduced in-hospital mortality risk (RR: 0.30, 95% CI: 0.15\u20130.60; I\n          2: 58%) compared with the prophylactic one. However, the former was also associated with a higher risk of bleeding (RR: 2.53, 95% CI: 1.60\u20134.00; I\n          2: 65%). Anticoagulant use, mainly heparin, reduced all-cause mortality in COVID-19 patients during hospitalization. Due to the higher risk of bleeding at therapeutic doses, the use of prophylactic dosages of anticoagulant is probably to be preferred in noncritically ill COVID-19 patients.<\/jats:p>","DOI":"10.1055\/s-0041-1726034","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T21:08:13Z","timestamp":1618348093000},"page":"372-391","source":"Crossref","is-referenced-by-count":59,"title":["Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis"],"prefix":"10.1055","volume":"47","author":[{"given":"Roberta","family":"Parisi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention. IRCCS Neuromed, via dell'Elettronica, Pozzilli, Isernia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention. IRCCS Neuromed, via dell'Elettronica, Pozzilli, Isernia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Di Castelnuovo","sequence":"additional","affiliation":[{"name":"Mediterranea Cardiocentro, Via Orazio n.2, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"de Gaetano","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention. IRCCS Neuromed, via dell'Elettronica, Pozzilli, Isernia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Benedetta","family":"Donati","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention. IRCCS Neuromed, via dell'Elettronica, Pozzilli, Isernia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Iacoviello","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention. IRCCS Neuromed, via dell'Elettronica, Pozzilli, Isernia, Italy"},{"name":"Research Center in Epidemiology and Preventive Medicine (EPIMED), Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003412","article-title":"Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19)","author":"W Luo","year":"2020","journal-title":"Preprints"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/his.14134","article-title":"Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction","volume":"77","author":"T Menter","year":"2020","journal-title":"Histopathology"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/jth.14844","article-title":"Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19","volume":"18","author":"M Dolhnikoff","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/jth.14888","article-title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"S Middeldorp","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2020.06.029","article-title":"The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management","volume":"194","author":"M Y Abou-Ismail","journal-title":"Thromb Res"},{"issue":"23","key":"ref6","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"B Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s00270-020-02532-3","article-title":"Heparin-related major bleeding in covid-19-positive patient: perspective from the outbreak","volume":"43","author":"P Lucatelli","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"N Tang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike s1 receptor-binding domain with heparin","volume":"120","author":"C J Mycroft-West","year":"2020","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"L211","DOI":"10.1152\/ajplung.00199.2020","article-title":"Heparin as a therapy for COVID-19: current evidence and future possibilities","volume":"319","author":"J A Hippensteel","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"03","key":"ref14","first-page":"167","article-title":"COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)","volume":"18","author":"M Marietta","year":"2020","journal-title":"Blood Transfus"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"J Thachil","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11239-020-02138-z","article-title":"Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum","volume":"50","author":"G D Barnes","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/s13063-020-04475-z","article-title":"Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol","volume":"21","author":"M Marietta","year":"2020","journal-title":"Trials"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1186\/s13063-020-04689-1","article-title":"Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"N Kharma","year":"2020","journal-title":"Trials"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"N Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.23.20076851","article-title":"Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment","author":"X Liu","year":"2020","journal-title":"MedRxiv"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/jth.14869","article-title":"High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients","volume":"18","author":"J F Llitjos","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11239-020-02162-z","article-title":"The association between treatment with heparin and survival in patients with Covid-19","volume":"50","author":"L Ayerbe","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.30.20117929","article-title":"Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated COVID-19 patients","author":"M Trinh","year":"2020","journal-title":"MedRxiv"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood.2020006941","article-title":"Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study","volume":"136","author":"D Tremblay","year":"2020","journal-title":"Blood"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","article-title":"Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19","volume":"76","author":"I Paranjpe","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1111\/jth.15022","article-title":"The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience","volume":"18","author":"R Pesavento","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"104965","DOI":"10.1016\/j.phrs.2020.104965","article-title":"Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study","volume":"159","author":"V Russo","year":"2020","journal-title":"Pharmacol Res"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/jcph.1749","article-title":"Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: a retrospective cohort study","volume":"60","author":"J Ferguson","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijcard.2020.09.001","article-title":"Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience","volume":"323","author":"M Schiavone","year":"2021","journal-title":"Int J Cardiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijcard.2020.09.062","article-title":"The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: a retrospective, observational study in Northern Italy","volume":"324","author":"A Desai","year":"2021","journal-title":"Int J Cardiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.thromres.2020.09.030","article-title":"Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia","volume":"196","author":"A Hsu","year":"2020","journal-title":"Thromb Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"100562","DOI":"10.1016\/j.eclinm.2020.100562","article-title":"Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study","volume":"27","author":"F Albani","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/ejh.13533","article-title":"Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis","volume":"106","author":"F Ionescu","year":"2021","journal-title":"Eur J Haematol"},{"issue":"16","key":"ref37","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2020.08.041","article-title":"Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19","volume":"76","author":"G N Nadkarni","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2020.10.031","article-title":"The effect of anticoagulation on clinical outcomes in novel coronavirus (COVID-19) pneumonia in a U.S. cohort","volume":"197","author":"L Lynn","year":"2021","journal-title":"Thromb Res"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1055\/s-0040-1720978","article-title":"Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality","volume":"120","author":"H H Billett","year":"2020","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40520-020-01750-6","article-title":"Prophylactic or therapeutic doses of heparins for COVID-19 infection? A retrospective study","volume":"33","author":"F Bolzetta","year":"2021","journal-title":"Aging Clin Exp Res"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"ofaa563","DOI":"10.1093\/ofid\/ofaa563","article-title":"Role of low-molecular-weight heparin in hospitalized patients with severe acute respiratory syndrome coronavirus 2 pneumonia: a prospective observational study","volume":"7","author":"M Falcone","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.thromres.2020.11.020","article-title":"Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: a cohort study in the early epidemic era","volume":"198","author":"W Qin","year":"2020","journal-title":"Thromb Res"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/s13054-020-03375-7","article-title":"Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients","volume":"24","author":"S Jonmarker","year":"2020","journal-title":"Crit Care"},{"issue":"06","key":"ref44","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5144\/0256-4947.2020.462","article-title":"Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection","volume":"40","author":"K Canoglu","year":"2020","journal-title":"Ann Saudi Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.09.20246579","article-title":"Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States","author":"C T Rentsch","journal-title":"medRxiv"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11739-020-02585-9","article-title":"Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19 [ePub ahead of print, 2021 Jan 3]","author":"I Martinelli","year":"2021","journal-title":"Intern Emerg Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-020-07133-3","article-title":"The association of low molecular weight heparin use and in-hospital mortality among patients hospitalized with COVID-19 [ePub ahead of print, 2021 Jan 4]","author":"L Shen","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1055\/a-1347-6070","article-title":"Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study [ePub ahead of print, 2021]","author":"A Di Castelnuovo","year":"2021","journal-title":"Thromb Haemost"},{"key":"ref50","volume-title":"Assessing the risk of bias of individual studies in systematic reviews of health care interventions. 2012 Mar 8","author":"M Viswanathan","year":"2008"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijid.2020.08.023","article-title":"A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19","volume":"100","author":"Y F Lu","year":"2020","journal-title":"Int J Infect Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjcard.2020.08.005","article-title":"The effect of anticoagulation use on mortality in COVID-19 infection","volume":"134","author":"H M Salah","year":"2020","journal-title":"Am J Cardiol"},{"key":"ref53","first-page":"e2180","article-title":"Anticoagulation outcomes in hospitalized Covid-19 patients: a systematic review and meta-analysis of case-control and cohort studies","volume":"2180","author":"A M Kamel","year":"2020","journal-title":"Rev Med Virol"},{"issue":"12","key":"ref54","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.18632\/aging.103583","article-title":"ADL-dependency, D-dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19","volume":"12","author":"G Bousquet","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1002\/ctm2.40","article-title":"Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan, China","volume":"10","author":"F Chen","year":"2020","journal-title":"Clin Transl Med"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"104931","DOI":"10.1016\/j.phrs.2020.104931","article-title":"30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study","volume":"158","author":"A Giacomelli","year":"2020","journal-title":"Pharmacol Res"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jinf.2020.06.027","article-title":"Clinical characteristics and 28-day mortality of medical patients admitted with COVID-19 to a central London teaching hospital","volume":"81","author":"K Khalil","year":"2020","journal-title":"J Infect"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1726034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T18:42:00Z","timestamp":1622572920000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1726034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":50,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1726034","relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]}}}